Thermo Fisher Scientific: Biopharma Recovery And Share Gains Support The Upside (NYSE:TMO)
· seekingalpha.com
Thermo Fisher rated Buy: accelerating organic growth, margin gains, and acquisitions boosting Pharma/Biotech exposure. Click for more on TMO stock.
Thermo Fisher Scientific's ( TMO ) end markets have begun to rebound from a relatively muted period with organic revenue growth accelerating to 5% in Q2 2026. P...